부산대학교 도서관

To the best of our knowledge, this is the largest cohort of Asian HCV patients treated with SOF/VEL/VOX to date, with the majority being "difficult to treat" (78% were genotype 3 with prior SOF/VEL exposure). Whether SOF/VEL/VOX resulted in a lower SVR12 rates among genotype-3 HCV patients remained debatable.7-9,11,12 In this Asian cohort, effectiveness seemed comparable among genotype 3 HCV patients. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. I To the Editor, i Hepatitis C virus (HCV) infection affects over 10 million people in Asia, with widely varying distributions of HCV genotypes across the region and greater heterogeneity than in North America and Europe.1,2 While current pan-genotypic direct-acting antivirals (DAAs) are highly efficacious, treatment failures still exist, particularly among patients with genotype 3 and decompensated cirrhosis.3,4 Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is indicated as rescue therapy in the event of DAA failure5 - based on landmark phase 3 trials demonstrating a high sustained virological response rate at 12 weeks (SVR12) of 96-98% in DAA-experienced HCV patients.6 However, data on the efficacy and safety of SOF/VEL/VOX among genetically diverse Asian HCV patients remain scarce. [Extracted from the article]